Atomoxetine [clinicaltrials_resource:NCT00191386/group/E1]
0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
Myopia for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/10/count/10]Abdominal pain for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/11/count/11]Constipation for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/12/count/12]Dental caries for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/13/count/13]Diarrhoea for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/14/count/14]Nausea for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/15/count/15]Stomatitis for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/16/count/16]Toothache for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/17/count/17]Vomiting for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/18/count/18]Malaise for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/19/count/19]Pyrexia for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/20/count/20]Bronchitis for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/21/count/21]Gastroenteritis for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/22/count/22]Gastroenteritis viral for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/23/count/23]Impetigo for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/24/count/24]Influenza for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/25/count/25]Nasopharyngitis for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/26/count/26]Otitis media for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/27/count/27]Pharyngitis for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/28/count/28]Rhinitis for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/29/count/29]Arthropod sting for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/30/count/30]Contusion for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/31/count/31]Excoriation for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/32/count/32]Fall for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/33/count/33]Joint sprain for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/34/count/34]Decreased appetite for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/35/count/35]Skin papilloma for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/36/count/36]Headache for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/37/count/37]Somnolence for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/38/count/38]Cough for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/39/count/39]Epistaxis for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/40/count/40]Oropharyngeal pain for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/41/count/41]Rhinitis allergic for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/42/count/42]Upper respiratory tract inflammation for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/43/count/43]Eczema for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/44/count/44]Urticaria for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/45/count/45]Tooth extraction for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/46/count/46]Total, other adverse events for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/8/count/8]Conjunctivitis allergic for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/other_events/9/count/9]Total, serious adverse events for NCT00191386 for E1 in NCT00191386 [clinicaltrials_resource:NCT00191386/serious_events/1/count/1]
group [clinicaltrials_vocabulary:group]
Atomoxetine [clinicaltrials_resource:NCT00191386/group/E1]
0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
Bio2RDF identifier
NCT00191386/group/E1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00191386/group/E1
group id [clinicaltrials_vocabulary:group-id]
description
0.5 milligrams per kilogram (m ...... for 6 months and up to 4 years
@en
identifier
clinicaltrials_resource:NCT00191386/group/E1
title
Atomoxetine
@en
type
label
Atomoxetine [clinicaltrials_resource:NCT00191386/group/E1]
@en